- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Royalty Pharma Plc (RPRX)
Assess today's live Royalty Pharma Plc (RPRX) share price, performance and insights using our live NASDAQ: RPRX stock exchange data.
Analyse the historical data and Royalty Pharma Plc share price performance charts on this page. Our technical summary section provides analysis on Royalty Pharma share price buy/sell indicators using real-time data (or discuss the Royalty Pharma (RPRX) stock price today with other investors in the Royalty Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ RPRX share price (ISIN: GB00BMVP7Y09) to enhance your trading decisions with our free investment tools and resources.
What Is the Royalty Pharma Plc Share Price Today?
The Royalty Pharma share price today is 39.39.
What Is the Stock Symbol for Royalty Pharma Plc
The stock symbol (or 'ticker') for Royalty Pharma Plc is "RPRX."
What Stock Exchange Does Royalty Pharma Plc Trade On?
Royalty Pharma Plc is listed and trades on the NASDAQ stock exchange.
Is Royalty Pharma Plc a Good Stock to Buy?
Determining whether Royalty Pharma Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Royalty Pharma Plc share price performance charts on this page. Our technical summary section provides analysis on Royalty Pharma share price buy/sell indicators using real-time data (or discuss the Royalty Pharma (RPRX) stock price today with other investors in the Royalty Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ RPRX share price (ISIN: GB00BMVP7Y09) to enhance your trading decisions with our free investment tools and resources.
What Is the Royalty Pharma Plc Share Price Today?
The Royalty Pharma share price today is 39.39.
What Is the Stock Symbol for Royalty Pharma Plc
The stock symbol (or 'ticker') for Royalty Pharma Plc is "RPRX."
What Stock Exchange Does Royalty Pharma Plc Trade On?
Royalty Pharma Plc is listed and trades on the NASDAQ stock exchange.
Is Royalty Pharma Plc a Good Stock to Buy?
Determining whether Royalty Pharma Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.63
39.50
52 wk Range
25.16
41.24
RPRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.6339.50
52 wk Range
25.1641.24
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.23%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.23%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RPRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
46.32
Upside
+17.59%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 6 consecutive years
- Form 8K Royalty Pharma Plc For: 22 December
- Investing.com
- Form 144 Royalty Pharma plc For: 15 December
- Investing.com
- Form 8K Royalty Pharma Plc For: 22 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Royalty Pharma Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma Plc Earnings Call Summary for Q3/2025
- Portfolio receipts rose 11% to $814 million in Q3 2025, with strong performance from Voranigo, Tremfya, and Cystic Fibrosis Franchise
- Royalty Pharma raised full-year 2025 guidance to $3.2-$3.25 billion in portfolio receipts, representing 14-16% growth despite stock declining 0.77% premarket
- Company deployed $1 billion in capital during Q3 while maintaining strong financial metrics with portfolio cash flow of $657 million and 81% margin
- CEO Pablo Legorreta emphasized the company's leadership position and best-in-class investment platform in innovative pharmaceutical products
- Management anticipates minimal royalties from Promacta in 2026 due to generic launches, highlighting potential challenges despite current robust performance
Last Updated: 05/11/2025, 14:12
Read Full TranscriptCompare RPRX to Peers and Sector
Metrics to compare | RPRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRPRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 22.0x | 3.7x | −0.6x | |
PEG Ratio | −0.70 | 0.24 | 0.00 | |
Price/Book | 3.5x | 2.7x | 2.6x | |
Price / LTM Sales | 9.7x | 2.7x | 3.2x | |
Upside (Analyst Target) | 14.2% | 26.1% | 41.8% | |
Fair Value Upside | Unlock | 23.7% | 5.1% | Unlock |
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 46.32
(+17.59% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
1.17 / 0.9936
Revenue / Forecast
814.00M / 734.92M
People Also Watch
FAQ
What Is the Royalty Pharma (RPRX) Share Price Today?
The live Royalty Pharma share price today is 39.39
What Stock Exchange Does Royalty Pharma (RPRX) Trade On?
Royalty Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Royalty Pharma?
The stock symbol (also called a 'ticker') for Royalty Pharma is "RPRX."
Does Royalty Pharma Pay Dividends? What’s The Current RPRX Dividend Yield?
Yes, RPRX Pays Dividends to its Shareholders. The current Royalty Pharma dividend yield is 2.23%.
What Is the Current Royalty Pharma Market Cap?
As of today, Royalty Pharma market capitalisation is 22.74B.
What Is Royalty Pharma's (RPRX) Earnings Per Share (TTM)?
The Royalty Pharma EPS is currently 1.75 (Trailing Twelve Months).
When Is the Next Royalty Pharma Earnings Date?
Royalty Pharma's next earnings report will be released on 17 Feb 2026.
Is RPRX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Royalty Pharma moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Royalty Pharma Stock Split?
Royalty Pharma has split 0 times. (See the RPRX stock split history page for full effective split date and price information.)
What is the current trading status of Royalty Pharma (RPRX)?
As of 24 Dec 2025, Royalty Pharma (RPRX) is trading at a price of 39.39, with a previous close of 38.86. The stock has fluctuated within a day range of 38.63 to 39.50, while its 52-week range spans from 25.16 to 41.24.
What Is Royalty Pharma (RPRX) Price Target According to Analysts?
The average 12-month price target for Royalty Pharma is USD46.31778, with a high estimate of USD56 and a low estimate of USD38. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +17.59% Upside potential.
What Is the RPRX Premarket Price?
RPRX's last pre-market stock price is 38.78. The pre-market share volume is 297.00, and the stock has decreased by -0.08, or -0.21%.
What Is the RPRX After Hours Price?
RPRX's last after hours stock price is 39.96, the stock has decreased by 0.57, or 1.45%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.